A5035664172- Intraperitoneal and Appendiceal Malignancies
- Appendicitis Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Ovarian cancer diagnosis and treatment
- Cutaneous Melanoma Detection and Management
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Hernia repair and management
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Pancreatitis Pathology and Treatment
- Occupational and environmental lung diseases
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Nonmelanoma Skin Cancer Studies
- Neuroblastoma Research and Treatments
- Polyomavirus and related diseases
- Gastrointestinal disorders and treatments
- Helicobacter pylori-related gastroenterology studies
- Breast Cancer Treatment Studies
- Radiomics and Machine Learning in Medical Imaging
- Antenna Design and Analysis
Mayo Clinic in Arizona
2014-2025
Mayo Clinic
2014-2024
WinnMed
2012-2024
Mayo Clinic in Florida
2013-2023
Pancreas Centre (Canada)
2022
The Ohio State University
2021
University of Minnesota
2020
University of Pittsburgh Medical Center
2020
American College of Surgeons
2019
Centre Hospitalier de l’Université de Montréal
2019
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management patients with NSCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. Patients metastatic lung cancer who are eligible targeted therapies or immunotherapies now surviving longer. This selection from the NSCLC focuses on actionable mutations.
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations management of disease in patients with NSCLC. These Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options eligible resectable
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance relapse, and subsequent treatment. panel has updated list recommended targeted therapies based on recent FDA approvals clinical data. This selection from NSCLC focuses advanced or metastatic actionable molecular biomarkers.
Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly predicts response, and biochemical (CA 19-9) markers are not useful (nonsecretors/nonelevated) many patients. Pathologic response highly survival post-NAT, but only known postoperatively. Because metabolic (FDG-PET) reveals primary tumor viability, this study aimed to evaluate our experience with preoperative FDG-PET...
Background: Accurate staging prior to resection of pancreatic ductal adenocarcinoma (PDAC) is imperative avoid unnecessary operative morbidity and oncologic futility in patients with occult intraabdominal distant metastases. We aimed determine the diagnostic yield laparoscopy (SL) identify factors associated increased risk positive (PL) modern era. Study Design: Patients radiographically localized PDAC who underwent SL 2017-2021 were retrospectively reviewed. The was defined as proportion...
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of pleura and other sites, estimated to occur in approximately 3,500 people United States annually. Pleural mesothelioma most common type represents 85% these cases. The NCCN Guidelines for Mesothelioma: provide recommendations diagnosis, evaluation, treatment, follow-up patients with pleural mesothelioma. These Insights highlight significant updates Pleural, including revised guidance on disease classification...
Low grade appendiceal mucinous neoplasms (LAMN) are indolent tumors that lack invasive potential but may present as pseudomyxoma peritonei. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves both overall recurrence free survival. While systemic is generally considered ineffective for LAMN, little literature available to support this notion. We evaluated outcomes individuals with LAMN who did not receive in combination CRS+HIPEC. A...
Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC). The identification a chemotherapeutic regimen that both effective and tolerable critical NAC to be oncologic benefit. After initial first-line (FL) NAC, some have lack response or therapeutic toxicities precluding further the same regimen; optimal decision making regarding this patient population unclear....
Cytoreductive surgery (CRS) is one of the most complex operations in surgical oncology with significant morbidity, and improved risk prediction tools are critically needed. Machine learning models can potentially overcome limitations traditional multiple logistic regression (MLR) provide accurate estimates.To develop validate an explainable machine model for predicting major postoperative complications patients undergoing CRS.This prognostic study used patient data from tertiary care...
Abstract Background The management of invasive intraductal papillary mucinous cystic neoplasm (I-IPMN) does not differ from de novo pancreatic ductal adenocarcinoma (PDAC); however, I-IPMNs are debated to have better prognosis. Despite being managed similarly PDAC, no data available on the response I-IPMN neoadjuvant chemotherapy. Methods All patients undergoing resection for a 2011 2022 were included. PDAC and cohorts compared evaluate therapy (NAT) overall survival (OS). Results This study...
In order to characterize the degree of immunosuppression in regional immunity patients with melanoma, we used immunohistochemistry analyze markers T-cell subtype and polarity, costimulation, dendritic cell maturation, monocytes, lymphatic vasculature, angiogenesis. Specifically, analyzed expression CD4, CD8, CD14, CD40, CD86, CD123, HLA-DR, IL-10, LYVE, VEGFR3, VEGF-C lymph nodes. We compared sentinel nodes without metastasis from melanoma both infection inflamed (reactive) dormant human...
Minimally invasive inguinal lymph node dissection (MILND) is a novel approach to lymphadenectomy. SAFE-MILND (NCT01500304) multicenter, phase I/II clinical trial evaluating the safety and feasibility of MILND for patients with melanoma in group surgeons newly adopting procedure.Twelve from 10 institutions without any previous experience, enrolled into prospective study after completing specialized training including didactic lectures, participating hands-on cadaveric laboratory, being...
Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated improved survival for patients colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant (NAC) prior to CRS-HIPEC poorly understood. A retrospective review adult CR-PM who underwent CRS+/-HIPEC from 2000–2017 was performed. Among 298 CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) first (SF). Patients had lower cancer index score (12.1 + 7.9 vs. 14.3 8.5, p =...
Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The for PeM provide recommendations workup, diagnosis, treatment primary as well previously treated PeM. diagnosis may be delayed because mimics diseases conditions disease so rare. pathology section was recently updated to include new information about markers used identify...
Pseudomyxoma peritonei (PMP) is primarily the result of a ruptured mucinous appendix neoplasm (MAN). Often MAN lumped with but biologically distinct from intestinal appendiceal adenocarcinoma. Nodal and systemic dissemination are rare peritoneal cavity being primary site recurrence. Routine performance right hemicolectomy (RHC) for PMP/MAN has been extensively debated without consensus. Our objective was to ascertain whether RHC survival advantage over appendectomy. We hypothesize if...